Euglycemic DKA (euDKA) as a presentation of COVID‐19. Issue 1 (20th November 2020)

• Record Type: Journal Article
• Authors: Dass, Bhagwan; Beck, Andrew; Holmes, Cody; Morton, Glenville
• Is Part Of: Clinical case reports. Volume 9:Issue 1(2021)
• Page Start: 395
• Page End: 398
• Publication Date: 2020-11-20
• Subjects: COVID‐19 -- diabetes -- diabetes mellitus -- diabetes type 2 -- diabetic ketoacidosis -- euglycemia -- type I diabetes mellitus; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.3540
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: COVID‐19 in the setting of SGLT2 inhibitor use may precipitate euglycemic DKA separate from known acute viral illness and dehydration precipitants. There should be consideration of proactive discontinuation of these medications in these patients. Abstract : COVID‐19 in the setting of SGLT2 inhibitor use may precipitate euglycemic DKA separate from known acute viral illness and dehydration precipitants. There should be consideration of proactive discontinuation of these medications in these patients.